IDEX (IEX) Q1 2026 earnings review
Record Orders and AI Tailwinds Propel Guidance Hike
IDEX delivered a robust start to 2026, breaking records with $988 million in orders and driving a guidance hike across the board. The Health & Science Technologies (HST) segment remains the clear engine, surging 11% organically on the back of AI-driven data center and semiconductor demand. The strength in HST more than offset lingering weakness in the Fire & Safety/Diversified Products (FSDP) segment, allowing total organic sales to accelerate to 5%. While gross margins saw a slight 40 bps compression due to unfavorable mix and price/cost pressures, operating leverage ultimately expanded adjusted EBITDA margins to 26.0%. The definitive trend is acceleration, signaling that the company is successfully pivoting from 2025's stagnant industrial environment into a higher-growth tech-oriented cycle.
🐂 Bull Case
Driven by AI infrastructure (data center power) and semiconductor markets, HST reported 11% organic sales growth and a 100 bps expansion in Adjusted EBITDA margins, proving out IDEX's M&A strategy in advanced technologies.
Management confidently raised FY26 organic sales growth guidance from 1-2% to 3-4%, and pushed adjusted EPS up by $0.20 at the midpoint. Orders remain structurally elevated at near $1 billion, providing immense backlog visibility.
🐻 Bear Case
Consolidated gross margin contracted by 40 bps to 44.9%. Unfavorable product mix and persistent price/cost pressure highlight that IDEX is having to absorb some costs that it cannot immediately pass through to customers.
Free cash flow fell YoY to $86 million, and FCF conversion collapsed from 69% in 25Q1 to just 58% in 26Q1 due to the timing of customer payments and higher capital expenditures.
⚖️ Verdict: 🟢
Bullish. Double-digit order growth combined with a meaningful upward guidance revision overshadows minor margin mix issues. IDEX is successfully monetizing AI data center and semiconductor tailwinds, structurally accelerating its growth profile compared to historical industrial averages.
Key Themes
AI and Semiconductor Demand Fueling HST Breakout
The Health & Science Technologies (HST) segment is breaking away from the broader industrial portfolio, posting 11% organic sales growth. The acceleration is directly tied to the build-out of AI-driven data center power infrastructure and semiconductor market strength. This growth is heavily supported by recent platform M&A, transforming IDEX from a traditional pump manufacturer into a critical component supplier for advanced tech infrastructure.
80/20 Framework Defends Bottom Line
Despite a 40 bps drop in gross margin caused by unfavorable mix and pressured price/cost dynamics, IDEX managed to expand its consolidated Adjusted EBITDA margin by 50 bps to 26.0%. Management credited the rigorous application of their '80/20' playbook, which drove net productivity improvements and better resource allocation toward high-growth platforms, mitigating underlying cost pressures.
FSDP Segment Reversing to Negative
While total IDEX organic sales grew 5%, the Fire & Safety/Diversified Products (FSDP) segment acted as a laggard, reversing to a 1% organic decline. This was primarily driven by lower volumes in the Dispensing businesses, tied to the timing of projects. The segment remains heavily reliant on stagnant municipal and general industrial funding cycles.
Working Capital Impacting Cash Flow Conversion
Operating cash flow moved oppositely to Net Income. While GAAP Net Income rose 25%, operating cash flow dropped slightly to $103.7 million. Management cited the 'timing of customer payments,' which dragged free cash flow conversion down to an uncharacteristically low 58% (from 69% a year prior). If accounts receivable collections do not normalize, it could restrict IDEX's aggressive M&A and buyback cadence.
Other KPIs
Accelerating. Orders jumped 13% on a reported basis and 10% organically. This marks the fifth consecutive quarter of positive organic order growth and sets an all-time quarterly high, providing IDEX with exceptional visibility for the remainder of FY26.
Accelerating. A 14% increase from $1.75 in 25Q1, heavily outpacing the 9% reported revenue growth. The upside was driven by aggressive share repurchases ($76.3M in the quarter) and improved operational leverage, despite a higher interest environment.
Guidance
Accelerating. Raised from previous guidance of 1.0% - 2.0%. This represents a significant step up from the 1.0% organic growth recorded in FY25, highlighting management's conviction in the sustained velocity of HST and the normalization of destocking in FMT.
Accelerating. Raised from previous guidance of $8.15 - $8.35. The midpoint ($8.45) implies a 6.3% YoY growth rate over FY25's $7.95, a notable improvement following the relatively flat earnings environment IDEX endured through 2024 and 2025.
Accelerating sequentially. This guide implies that the strong 5% organic growth seen in Q1 was not just a timing anomaly, but a structural run-rate that will carry into the middle of the year.
Key Questions
Gross Margin Headwinds vs AI Mix
Given the explosive growth in AI data center and semiconductor markets within HST, why did consolidated gross margin contract by 40 bps? Is the new high-growth tech mix structurally lower gross margin than your legacy industrial businesses?
Cash Collection Normalization
Free cash flow conversion dropped to 58% primarily due to the timing of customer payments. When do you expect accounts receivable metrics to normalize, and does this reflect changing payment terms demanded by larger tech customers?
FSDP Segment Inflection
With FSDP organic sales declining 1% due to project timing in Dispensing, what is the line of sight for an inflection point in this segment, and does the 80/20 framework suggest eventual divestitures here to focus entirely on HST?